Full text
Earnings transcript
Read the complete earnings call transcript.
BNTX
BioNTech SE
$86.5
1
(1.17%)
| Exchange: | NASDAQ |
| Market Cap: | 21.874B |
| Shares Outstanding: | 226.859M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Ugur Sahin | |||||
| Full Time Employees: | 6772 | |||||
| Address: |
| |||||
| Website: | https://www.biontech.de |
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech’s portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 3,819,000 | 2,751,100 | 2,756,632.777 |
| Gross Profit | 3,219,200 | 2,209,800 | 2,140,162.894 |
| EBITDA | 1,377,400 | -367,100 | -256,174.069 |
| Operating Income | 690,400 | -1,314,300 | -623,865.983 |
| Net Income | 930,300 | -665,300 | -1,091,261.192 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 23,006,300 | 22,529,700 | 21,979,241.541 |
| Total Liabilities | 2,760,400 | 3,118,600 | 2,763,223.457 |
| Total Stockholders Equity | 20,245,900 | 19,411,100 | 19,216,018.084 |
| Total Debt | 219,100 | 254,200 | 267,286.193 |
| Cash and Cash Equivalents | 11,663,700 | 9,761,900 | 7,672,133.311 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 5,371,400 | 207,700 | 438,002.907 |
| Capital Expenditure | -705,500 | -452,300 | -168,189.271 |
| Free Cash Flow | 4,665,900 | -244,600 | 269,813.636 |
| Net Income | 1,186,100 | -665,300 | -1,091,261.192 |
| Net Change in Cash | -2,211,400 | -1,901,800 | -931,166.313 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 2,712,131.072 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 3,678,045.420 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 3,169,212.271 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 912,043.551 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 1,236,864.119 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 1,065,752.185 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | -593,139.053 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | -398,710.738 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | -490,716.261 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 361,011.972 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 489,584.904 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 421,854.085 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | -2.030 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | -1.650 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | -2.450 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 13 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 5 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Performance in COVID-19 Vaccines: BioNTech reported €1.245 billion in revenues for Q3 2024, driven primarily by its COVID-19 vaccine sales, showcasing its strong market position in this segment as highlighted in the latest earnings call transcript.
- Strong Balance Sheet Metrics: The company maintains a healthy financial position with significant cash and cash equivalents, high current and quick ratios (as per Key Metrics TTM), indicating liquidity and ability to cover short-term liabilities.
- Innovation in Oncology Pipeline: The earnings call emphasized a robust oncology strategy with multiple clinical trials advancing, positioning BioNTech as a potential leader in innovative cancer treatments.
- Operational Efficiency: High gross profit margins (TTM data) and positive free cash flow (Cash Flow Statements) reflect efficient operations and capacity for reinvestment in R&D.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about BNTX valuation
Is BioNTech SE (BNTX) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for BioNTech SE (BNTX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is BNTX a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether BNTX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is BNTX’s P/E ratio?
You can see BNTX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for BNTX?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is BNTX a good long-term investment?
Whether BNTX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
BNTX
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.17
Trading Metrics:
| Open: | 86.64 | Previous Close: | 85.5 | |
| Day Low: | 84.96 | Day High: | 87.05 | |
| Year Low: | 79.52 | Year High: | 124 | |
| Price Avg 50: | 94.78 | Price Avg 200: | 100.16 | |
| Volume: | 1.166M | Average Volume: | 1.204M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeBNTX full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into BioNTech SE, ticker BNTX, a company that became a household name thanks to its groundbreaking work on COVID-19 vaccines. But there’s so much more to this biotech giant than just vaccines, and I’m excited to break it all down for you. We’ll cover everything from their financials to their pipeline, recent performance, and whether this stock is a buy for your portfolio. So, grab a coffee, stick around,…
